What is 3' bias exactly? I understand it is something caused by the enrichment of poly(A) mRNA using oligo(dT) primer.(or is that wrong?) How does it cause the 3' bias?
-
-
See this previous SeqAnswers thread: http://seqanswers.com/forums/showthread.php?t=9839 -
The thread does not explain what 3' bias is.Comment
-
Since polyA tails are at the 3'-end of mRNA's any method that uses polyA sequence for enrichment is likely to recover fragments from that end.
This leads to a greater chance of having sequences from the 3'-end in the resulting reads as opposed to reads that represent the 5'-end of the molecules.
Originally posted by numfar View PostComment
-
So the mRNA has been fragmented? Is this intentionally?(if so why?)Comment
-
Next generation sequencers, specifically those used for RNA-Seq experiments, require library fragments around 3-400 bases. However, RNA needs to be of good quality (non fragmented) at the beginning for successful mRNA enrichment (or rRNA removal)Originally posted by numfar View Post
Typical RNA-Seq workflow goes a bit like this (based on Illumina TruSeq method):
Enrich mRNA (usually PolyA enrichment by Oligo dT beads x2)
Fragment mRNA to required size (usually metal ion-catalyzed base hydrolysis fragmentation)
Reverse transcribe to make double stranded cDNA
Library prep (end repair, adenylate, ligate adapters, size select, PCR enrich)
QC and Quantify library
SequenceComment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment